S
Sheri L. Spunt
Researcher at Stanford University
Publications - 206
Citations - 7975
Sheri L. Spunt is an academic researcher from Stanford University. The author has contributed to research in topics: Rhabdomyosarcoma & Soft tissue sarcoma. The author has an hindex of 45, co-authored 185 publications receiving 6559 citations. Previous affiliations of Sheri L. Spunt include St. Jude Children's Research Hospital & Children's National Medical Center.
Papers
More filters
Journal ArticleDOI
End-of-Life Care Preferences of Pediatric Patients With Cancer
Pamela S. Hinds,Donna Drew,Linda L. Oakes,Maryam Fouladi,Sheri L. Spunt,Christopher Church,Wayne L. Furman +6 more
TL;DR: These children and adolescents with advanced cancer realized that they were involved in an end-of-life decision, understood the consequences of their decision, and were capable of participating in a complex decision process involving risks to themselves and others.
Journal ArticleDOI
Soft tissue sarcoma across the age spectrum: A population-based study from the surveillance epidemiology and end results database†
Andrea Ferrari,Iyad Sultan,Tseng Tien Huang,Carlos Rodriguez-Galindo,Ahmad Shehadeh,Cristina Meazza,Kirsten K. Ness,Michela Casanova,Sheri L. Spunt +8 more
TL;DR: Soft tissue sarcomas are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan and the impact of age on disease features and outcome is unclear.
Journal ArticleDOI
“Trying to Be a Good Parent” As Defined By Interviews With Parents Who Made Phase I, Terminal Care, and Resuscitation Decisions for Their Children
Pamela S. Hinds,Linda L. Oakes,Judy Hicks,Brent Powell,Deo Kumar Srivastava,Sheri L. Spunt,JoAnn Harper,Justin N. Baker,Nancy West,Wayne L. Furman +9 more
TL;DR: The definition of a good parent to a child with incurable cancer has not been formally defined and 15 clinician strategies that help parents be a part of making these decisions on behalf of a children with advanced cancer are identified.
Journal ArticleDOI
Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma
Xiang Chen,Elizabeth Stewart,Anang A. Shelat,Chunxu Qu,Armita Bahrami,Mark E. Hatley,Gang Wu,Cori Bradley,Justina McEvoy,Alberto S. Pappo,Sheri L. Spunt,Marcus B. Valentine,Virginia Valentine,Fred Krafcik,Walter H. Lang,Monika Wierdl,Lyudmila Tsurkan,Viktor Tolleman,Sara M. Federico,Christopher L. Morton,Charles Lu,Li Ding,John Easton,Michael Rusch,Panduka Nagahawatte,Jianmin Wang,Matthew Parker,Lei Wei,Erin Hedlund,David Finkelstein,Michael N. Edmonson,Sheila A. Shurtleff,Kristy Boggs,Heather L. Mulder,Donald Yergeau,Steve Skapek,Douglas S. Hawkins,Nilsa C. Ramirez,Philip M. Potter,John A. Sandoval,Andrew M. Davidoff,Elaine R. Mardis,Richard K. Wilson,Jinghui Zhang,James R. Downing,Michael A. Dyer +45 more
TL;DR: High-throughput screening of primary cultures derived from orthotopic xenografts of tumors that were sequenced identified oxidative stress as a pathway of therapeutic relevance for ERMS.
Journal ArticleDOI
Genome-Informed Targeted Therapy for Osteosarcoma
Leanne C. Sayles,Marcus R. Breese,Amanda Koehne,Stanley G. Leung,Alex G. Lee,Heng-Yi Liu,Aviv Spillinger,Avanthi Tayi Shah,Bogdan Tanasa,Krystal Straessler,Florette K. Hazard,Sheri L. Spunt,Neyssa Marina,Grace E. Kim,Soo-Jin Cho,Raffi S. Avedian,David G. Mohler,Mi-Ok Kim,Steven G. DuBois,Douglas S. Hawkins,E. Alejandro Sweet-Cordero +20 more
TL;DR: Using patient-derived tumor xenografts, it is demonstrated that targeting of patient-specific SCNAs leads to significant decrease in tumor burden, providing a road map for genome-informed treatment of osteosarcoma.